Study agents | Other agents | Disease | Dosage | Clinical trials | No. Pts. | Response | Reference |
---|
Idelalisib | Â | Relapsed | 150Â mg | Phase I | 54 | ORR:26% | [44, 45] |
Refractory |
Idelalisib | Rituximab | Relapsed | 150Â mg | Phase I | 51 | ORR:74/82/87% | [46] |
 | Bendamustine | Refractory |  |  |  | 1 year PFS:74/88/87% |  |
- Abbreviations: ORR overall response rate, PFS progression-free survival.